An international review of antidepressant research has found that several medicines may be more effective than fluoxetine at helping people with depression both improve and remain well over time. The analysis, published in The Lancet Psychiatry, compared evidence from 115 randomized clinical trials involving more than 30,000 participants.
The findings address a central question in depression care: which medicines are most likely not only to reduce symptoms initially, but also to support a sustained response after that improvement occurs. Depression affects nearly 6% of people worldwide, and many patients continue medication after symptoms improve in part to reduce the risk of relapse.
Looking beyond initial symptom improvement
Antidepressant studies often focus on short-term outcomes, such as whether symptoms improve during an initial treatment period. The new study instead compared medicines for both short- and long-term effectiveness, using fluoxetine as a familiar reference treatment.
Researchers examined 20 antidepressants and found evidence that medicines can help patients stay well during longer-term use. They also found that the medications did not perform identically: three treatments—escitalopram, agomelatine and duloxetine—were more effective than fluoxetine in the long-term comparison.
The results do not establish a universal best antidepressant. They do, however, give prescribers and guideline writers additional comparative evidence to consider when making an initial choice that could become a long-term treatment.
What the analysis found
Escitalopram, an SSRI already widely used in clinical practice, was among the medicines associated with stronger long-term effectiveness. Agomelatine and duloxetine also performed better than fluoxetine in the analysis.
- Escitalopram is already commonly prescribed and belongs to the SSRI class often recommended as a first treatment option.
- Agomelatine showed favorable effectiveness in the study, but the source notes a risk of liver failure as a potential side effect.
- Duloxetine was also among the stronger long-term performers, although it is prescribed less often as a first-line treatment, according to the researchers.
That distinction matters because long-term treatment decisions involve more than symptom scores. A medicine’s potential benefits must be weighed against its possible adverse effects, patient history and individual preferences.
Possible implications for treatment guidelines
Many international guidelines already advise starting with an SSRI. The study’s authors say the evidence for escitalopram could influence future guidance because it appeared effective for both initial and sustained response.
But the researchers explicitly caution against translating a population-level result into a single treatment rule. Eric Ruhé, a professor of difficult-to-treat depression at Radboud University Medical Center, said the findings do not mean every person with severe depression should receive escitalopram. The appropriate balance of benefits and side effects differs from person to person, he said.
That caveat is especially important for a condition as variable as depression. Two patients with similar symptom severity can have different prior medication experiences, coexisting health conditions, tolerances for side effects and treatment goals. The medicine that offers the most favorable average result in a comparison may not be the right option for every individual.
A broader evidence base for long-term care
The scale of the review is notable. Rather than relying on one trial or a direct head-to-head comparison between two drugs, the researchers synthesized evidence from 115 randomized clinical trials. That approach allowed them to compare a broad set of antidepressants and evaluate sustained response as a distinct outcome.
For clinicians, the work may be most useful at the beginning of treatment planning. When a patient may need to continue therapy after achieving improvement, evidence about maintenance effectiveness can be relevant from the first prescription rather than becoming an afterthought only once symptoms return.
For patients, the findings reinforce the importance of discussing both short- and long-term expectations with a prescriber. Medication changes, starts and discontinuations should be made with clinical guidance, particularly because individual side effects and risks can differ substantially.
What the study does not settle
The supplied report identifies comparative long-term effectiveness, but it does not eliminate the need for individualized care. It does not say that a drug that performed less well than another in the analysis is ineffective, nor does it provide a single medication choice for all forms or severities of depression.
Instead, the study adds a long-term dimension to a decision that already requires clinical judgment. Its central message is that sustained response can differ among antidepressants—and that evidence should inform the initial choice when continued treatment may be needed.
As treatment guidelines are updated and clinicians interpret the findings, the likely practical question will be how to combine this comparative evidence with safety considerations and each patient’s circumstances. The analysis offers a clearer starting point for that conversation, while leaving the final choice where it belongs: in an informed discussion between patient and prescriber.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
